Lipid Nanoparticle Composition for Low-Toxicity Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene delivery vectors, both viral and non-viral, face challenges such as high production costs, limited loading capacity, poor targeting properties, insertion integration, teratogenic mutagenesis, and toxicity issues, which hinder their clinical application, especially for repeated administration and in vivo transfection efficiency.
Innovation Solution
Development of a lipid compound nanoparticle comprising specific alkyl and alkyl derivatives, along with auxiliary materials like PEG derivatives and lipids, to form a nucleic acid nanoparticle complex for efficient gene delivery, offering good biocompatibility and high transfection efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for gene delivery, then transfection efficiency is improved, but production cost increases and safety risks (insertional mutagenesis, teratogenicity) worsen
Solution Approach 1:
The patent extracts and eliminates the harmful viral components (capsid, envelope, regulatory elements) while retaining only the essential gene delivery function through synthetic non-viral vectors, thereby removing insertional mutagenesis and teratogenicity risks while maintaining transfection capability
Solution Approach 2:
The patent employs composite lipid nanoparticle formulations combining ionizable lipids, PEGylated lipids, cholesterol, and auxiliary materials to achieve viral-level transfection efficiency without viral safety risks, creating a hybrid system that mimics viral delivery mechanisms while eliminating viral hazards
2Object-generated harmful factors
If liposome nanoparticles are used for gene delivery, then production cost decreases and safety improves, but transfection efficiency and biocompatibility worsen
Solution Approach 1:
The patent modifies key parameters of liposome nanoparticles by using ionizable lipids with pKa optimization, controlling particle size distribution, adjusting lipid composition ratios, and optimizing N/P ratios to enhance transfection efficiency while maintaining low toxicity and good biocompatibility
Solution Approach 2:
The patent creates composite lipid nanoparticle systems combining multiple lipid types (ionizable lipids, PEGylated lipids, cholesterol) with auxiliary materials to achieve synergistic effects that improve transfection efficiency while maintaining the safety and low cost advantages of non-viral vectors
3Ease of manufacture
If conventional liposome lipid materials are used, then production cost is reduced, but biodegradability decreases and toxicity increases
Solution Approach 1:
The patent selects ionizable lipids with specific molecular weight ranges (300-1000 Da) and incorporates biodegradable linkages (ester bonds, amide bonds) into the lipid structure, enabling metabolic breakdown into non-toxic components while maintaining manufacturing feasibility and cost-effectiveness
Solution Approach 2:
The patent designs lipid nanoparticles with biodegradable structures that can be metabolized and eliminated by the body, allowing the lipid components to be discarded through natural metabolic pathways while recovering therapeutic benefits, thereby reducing long-term toxicity
Data Source
AI summary
The invention relates to a compound, a lipid compound nanoparticle, a nucleic acid nanoparticle complex, a pharmaceutical composition and uses thereof in the drug delivery field, and belongs to the fields of biomedicine and biotechnology. The structure of the compound is shown as formula A. The compound, lipid compound nanoparticle or nucleic acid nanoparticle complex provided herein has the advantages of good biocompatibility, high transfection efficiency, low toxicity and excellent technical effects.